Head-to-head evidence
Diastat vs Stiripentol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diastat
Marketed by Bausch Health
NCT03953820 · Phase 1/2 · completed
The study randomized participants to treatment sequences and used Diastat as an active comparator, but it was open-label and small, with 31 randomized participants. Its primary endpoints were pharmacokinetic measures rather than clinical seizure outcomes, and the registry does not clearly report whether the primary comparison met its prespecified statistical criteria.
Stiripentol
Marketed by Biocodex
NCT07176832 · Phase 1 · completed
This is an open-label pharmacokinetic bioequivalence study comparing two formulations of the same already-marketed drug in healthy volunteers, not a controlled trial measuring clinical efficacy against a comparator or placebo.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diastat's landscape · Stiripentol's landscape